EUVIMEDEUVIMED entdecken
Multizentrische Studie

Gemcitabine and docetaxel for high‐risk non‐muscle‐invasive bladder cancer: EuroGemDoce group results

Pietro Scilipoti iD, Mattia Longoni, Mario de Angelis iD, Paolo Zaurito, Albane Massiet, Daniele Dutto, Francesco Soria iD, Mario Álvarez-Maestro, Alfredo Aguilera Bazán, Benjamin Pradere, Tobias Klatte iD, Roberto Contieri iD und 19 weitere

BJU International · 2025-06 · 135 (6) · 969-976

DOI: 10.1111/bju.16645 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift BJU International, online erschienen am 11.01.2025. Verfasst von Pietro Scilipoti und 30 weiteren Autor:innen. Beteiligte Einrichtung: Division of Experimental Oncology/Unit of Urology, IRCCS Ospedale San Raffaele, Milan, Italy. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Deoxycytidine, Docetaxel, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the oncological efficacy and safety of sequential intravesical gemcitabine/docetaxel (Gem/Doce) therapy in a European cohort of patients with high‐risk and very‐high‐risk non‐muscle‐invasive bladder cancer (NMIBC) after previous Bacillus Calmette–Guérin (BCG) treatment. Materials and Methods Data were retrospectively collected from 95 patients with NMIBC, treated with Gem/Doce at 12 European centres between 2021 and 2024. Patients previously treated with BCG who had completed a full induction course and received at least one follow‐up evaluation were included. One‐year disease‐free survival (DFS), high‐grade DFS and progression‐free survival (PFS) were estimated using Kaplan–Meier curves. Adverse events (AEs) were recorded through medical interviews.

Results

Of 75 patients, 63 (84%) were classified as having high‐risk and 12 (16%) as having very‐high‐risk NMIBC. Over a median (interquartile range) follow‐up of 9 (5–14) months, 20 patients (27%) relapsed and five (6.7%) underwent radical cystectomy. The 1‐year DFS was 73% (95% confidence interval [CI] 62–86%), 1‐year high‐grade DFS was 79% (95% CI 68–91%) and 1‐year PFS was 95% (95% CI 90–100%). AEs occurred in 34 patients (45%), with six (8.7%) experiencing severe AEs. Limitations of the study include the short follow‐up and variability in both treatment dwelling times and dosage across centres.

Conclusion

The intravesical Gem/Doce regimen demonstrated promising short‐term oncological outcomes and was well tolerated in this cohort of patients with high‐ and very‐high‐risk NMIBC previously treated with BCG. Prospective studies and randomised trials are awaited to define the ideal candidates for Gem/Doce therapy and to standardise treatment protocols.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsDeoxycytidineDocetaxelAntineoplastic Combined Chemotherapy ProtocolsHumansGemcitabineMaleFemaleAgedRetrospective StudiesMiddle AgedAdministration, IntravesicalEuropeNeoplasm InvasivenessBCG VaccineNon-Muscle Invasive Bladder Neoplasms

Stichwörter der Autor:innen

Europeadverse eventsdocetaxelgemcitabinenon‐muscle‐invasive bladder canceroncological outcomes

Substanzen

GemcitabineDeoxycytidineDocetaxelBCG Vaccine

Autor:innen und Institutionen

  • Division of Experimental Oncology/Unit of Urology, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Vita-Salute San Raffaele University, Milan, Italy.
  • Department of Urology, Bichat-Claude Bernard Hospital, AP-HP, Université de Paris Cité, Paris, France.
  • Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy.
  • Department of Urology, Hospital Universitario La Paz, Madrid, Spain.
  • Department of Urology UROSUD, La Croix Du Sud Hospital, Quint-Fonsegrives, France.

ORCID-Profile: Pietro Scilipoti, Mario de Angelis, Francesco Soria, Tobias Klatte, Roberto Contieri, José Daniel Subiela, Renate Pichler, Francesco Montorsi

Zitieren

APA

Scilipoti, P., Longoni, M., de Angelis, M., Zaurito, P., Massiet, A., Dutto, D., Soria, F., Álvarez-Maestro, M., Bazán, A. A., Pradere, B., Klatte, T., Contieri, R., Hurle, R., Krajewski, W., Subiela, J. D., Pichler, R., Szostek, A., Marcq, G., Elena, J. L. R., …, & Urothelial Carcinoma Working Group (2025). Gemcitabine and docetaxel for high‐risk non‐muscle‐invasive bladder cancer: EuroGemDoce group results. BJU International, 135(6), 969-976. https://doi.org/10.1111/bju.16645

Vancouver

Scilipoti P, Longoni M, de Angelis M, Zaurito P, Massiet A, Dutto D, et al. Gemcitabine and docetaxel for high‐risk non‐muscle‐invasive bladder cancer: EuroGemDoce group results. BJU International. 2025;135(6):969-976. doi:10.1111/bju.16645

BibTeX
@article{Scilipoti2025,
  author = {Scilipoti, Pietro and Longoni, Mattia and de Angelis, Mario and Zaurito, Paolo and Massiet, Albane and Dutto, Daniele and Soria, Francesco and Álvarez-Maestro, Mario and Bazán, Alfredo Aguilera and Pradere, Benjamin and Klatte, Tobias and Contieri, Roberto and Hurle, Rodolfo and Krajewski, Wojciech and Subiela, José Daniel and Pichler, Renate and Szostek, Aleksandra and Marcq, Gautier and Elena, José Luis Rodríguez and Aranda, Javier and Gontero, Paolo and Rouprêt, Morgan and Shariat, Shahrokh F and Necchi, Andrea and Montorsi, Francesco and Briganti, Alberto and Xylinas, Evanguelos and Moschini, Marco and EuroGemDoce Study Group Collaborators, EuroGemDoce Study Group Collaborators and European Association of Urology ‐ Young Academic Urologists (EAU‐YAU), European Association of Urology ‐ Young Academic Urologists (EAU‐YAU) and Urothelial Carcinoma Working Group, Urothelial Carcinoma Working Group},
  title = {Gemcitabine and docetaxel for high‐risk non‐muscle‐invasive bladder cancer: EuroGemDoce group results},
  journal = {BJU International},
  year = {2025},
  volume = {135},
  number = {6},
  pages = {969--976},
  doi = {10.1111/bju.16645}
}
Kostenlos starten →